Empiget-LT Tablets 25mg+5mg Film-Coated Tablet Kenya - English - Pharmacy and Poisons Board

empiget-lt tablets 25mg+5mg film-coated tablet

getz pharma (private) limited 29-30/27, korangi industrial area karachi 74900 - empagliflozin + linagliptin - film-coated tablet - 25mg + 5mg/film-coated tablet - metformin and empagliflozin

GLYXAMBI 10 MG5 MG Israel - English - Ministry of Health

glyxambi 10 mg5 mg

boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 10 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.

TRIJARDY XR- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release United States - English - NLM (National Library of Medicine)

trijardy xr- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - trijardy xr is a combination of empagliflozin, linagliptin, and metformin hydrochloride (hcl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use trijardy xr is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.2)] . trijardy xr has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trijardy xr [see warnings and precautions (5.3)]. trijardy xr is contraindicated in patients with: - severe renal impairment (egfr less than 30 ml/min/1.73 m2 ), end-stage renal disease,

Emglyza-25 Tablet Kenya - English - Pharmacy and Poisons Board

emglyza-25 tablet

unisel pharma (k) ltd apricot suites fourth parklands avenue, nairobi - empagliflozin - tablet - empagliflozin 25 mg - empagliflozin

JARDIANCE- empagliflozin tablet, film coated United States - English - NLM (National Library of Medicine)

jardiance- empagliflozin tablet, film coated

remedyrepack inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jardiance is not recommended in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m 2 . jardiance is likely to be ineffective in this setting based upon its mechanism of action. - hypersensitivity to empagliflozin or any of the excipients in jardiance, reactions such as angioedema have occurred [see

DIAJARD 25 MG TABLETS Film-Coated Tablet Kenya - English - Pharmacy and Poisons Board

diajard 25 mg tablets film-coated tablet

m/s. innocia lifesciences pvt. ltd. block a, no.12, balaji nagar, ambattur, chennai - empagliflozin - film-coated tablet - each film coated tablet contains: empagliflozin… - empagliflozin

Empaflo 25mg Tablets Film-Coated Tablet Kenya - English - Pharmacy and Poisons Board

empaflo 25mg tablets film-coated tablet

dawa ltd baba dogo road,ruaraka,p.o box 16633-00620 - empagliflozin - film-coated tablet - each film coated tablet contains: empagliflozin… - empagliflozin

XENGLU TABLETS 25mg Film-Coated Tablet Kenya - English - Pharmacy and Poisons Board

xenglu tablets 25mg film-coated tablet

hilton pharma (pvt.) ltd. plot no. 13-14, sector 15, korangi industrial - empagliflozin - film-coated tablet - each film coated tablet contains: empagliflozin… - empagliflozin

JARDIANCE DUO 12.5 MG500 MG Israel - English - Ministry of Health

jardiance duo 12.5 mg500 mg

boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 12.5 mg; metformin hydrochloride 500 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

JARDIANCE DUO 12.5 MG500 MG Israel - English - Ministry of Health

jardiance duo 12.5 mg500 mg

boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 12.5 mg; metformin hydrochloride 500 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.